Quick Answer
Protagenic Therapeutics, Inc.new reported Operating Income of -$5.70 million for fiscal year 2024.
Protagenic Therapeutics, Inc.new Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2024 | -$5.70M | -25.9% |
| 2023 | -$4.53M | -27.2% |
| 2022 | -$3.56M | +14.1% |
| 2021 | -$4.14M | -62.3% |
| 2020 | -$2.55M | -22.3% |
| 2019 | -$2.09M | +9.9% |
| 2018 | -$2.31M | +2.2% |
| 2017 | -$2.37M | -5.9% |
| 2016 | -$2.23M | -117.9% |
| 2015 | -$1.03M | -108.8% |
| 2015 | -$491.0K | +49.6% |
| 2014 | -$975.0K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$925.1K | -130.5% | +16.9% |
| September 30, 2025 | -$1.11M | -213.4% | +23.1% |
| March 31, 2025 | -$1.45M | +16.7% | -260.8% |
| December 31, 2024 | -$401.4K | — | -13.0% |
| September 30, 2024 | -$355.4K | +75.2% | +78.7% |
| June 30, 2024 | -$1.67M | -45.8% | +4.1% |
| March 31, 2024 | -$1.74M | -135.1% | -21.4% |
| September 30, 2023 | -$1.43M | -54.9% | -25.2% |
- Protagenic Therapeutics, Inc.new showed a decrease of -25.9% in Operating Income compared to the prior fiscal year.
- Over the 2014–2024 period, Protagenic Therapeutics, Inc.new’s operating income has declined by 484.7% (from -$975.0 thousand to -$5.70 million).
- The most recent figure is from Protagenic Therapeutics, Inc.new’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: